Generic semaglutide in Canada: what Health Canada's approval actually means

What did @ctvnewstoronto actually say?

The claim is fairly specific: Health Canada has approved a generic semaglutide made by Dr. Reddy's Laboratories, making Canada the first G7 country to authorize one. The reporter says this "opens the door to much cheaper weight loss drugs" and that the US and UK "won't see generic Ozempic for several more years."

To be clear about what was actually said: the approval is described as covering the "once-weekly treatment of Type 2" diabetes. Weight loss gets mentioned in the framing, but the formal approval is for diabetes. That distinction matters, and we'll get to it. The timeline given for patient access ranges from "the first half of this year to mid to late 2026," which is a wide spread that reflects genuine uncertainty rather than anything the reporter invented.

Overall the segment is more grounded than most TikTok health content. The caveats are present. The hype is moderate. But there are a few things worth unpacking.

Does the science back this up?

The core pharmacology is solid. Generic drugs contain the same active ingredient at the same dose and route of administration as the brand-name product. Health Canada's generic approval process requires bioequivalence data, meaning the generic must perform comparably in the body. That part of the "same active ingredient" framing is accurate.

Where it gets complicated is semaglutide's delivery system. Ozempic is a subcutaneous injectable with a specific pen device, formulation, and supply chain. Bioequivalence for injectables involves different regulatory considerations than for oral generics. A 2021 review by Christl et al. in the Journal of Pharmaceutical Sciences noted that demonstrating bioequivalence for complex injectables requires careful attention to device performance and formulation, not just the molecule itself.

The price reduction prediction is reasonable but not guaranteed. A 2023 analysis by Hernandez et al. in JAMA Health Forum found that generic entry in injectable drug categories historically produces more modest price competition than oral generics, partly because manufacturing complexity limits how many competitors enter the market quickly.

What did they get wrong (or right)?

The biggest issue is the casual slide between diabetes and weight loss. The Health Canada approval, as described, is for Type 2 diabetes treatment. Wegovy, the weight loss version of semaglutide, is a different product at a higher dose with a separate regulatory approval. The reporter says this opens the door to "much cheaper weight loss drugs" without clarifying that the generic approval is not automatically an approval for obesity treatment.

This is not a trivial distinction. A generic version of Ozempic approved for diabetes is not the same as a generic Wegovy. Patients seeking semaglutide for weight management would need either a separate generic approval for that indication or an off-label prescription, which comes with its own access and cost considerations. Conflating the two misleads viewers who are most likely watching because of interest in weight loss.

What they got right: the G7 first claim appears accurate based on available regulatory records. The patent situation in the US is also correctly characterized. Novo Nordisk's core semaglutide patents in the US are not expected to expire until the late 2020s at the earliest, with some estimates pushing meaningful generic competition to 2031 or beyond.

What should you actually know?

If you are in Canada and managing Type 2 diabetes, this approval is genuinely good news. More competition in the semaglutide market could reduce costs over time, though the timeline is uncertain and the price drop may be slower than what happened with oral drug generics.

If you are in Canada and interested in semaglutide for weight management specifically, this approval does not automatically give you access to a cheaper generic option for that use. The regulatory pathway for a generic version of Wegovy-equivalent dosing is a separate question.

If you are in the US or UK, nothing has changed for you today. Patent protections remain in place, and the legal landscape for generics in those markets has not shifted because of what Canada did.

• Generic approval means bioequivalence to the reference product, not identical manufacturing processes or devices.
• Injectable drug markets historically see slower price competition than oral generic markets after first approval.
• Health Canada's approval covers diabetes treatment. Weight management indications require separate review.
• Access timelines remain genuinely unclear. The six-month to eighteen-month range the reporter cited reflects real uncertainty, not evasion.